Abstract
Methods Clinical Records of 17 children (16 girls and 1 boy) were retrospectively analyzed over a period of 24 months (Mar 2012 to Mar 2014). All children satisfied the criteria for precocity based on clinical features, radiological assessment and GnRHa stimulation test. All 16 girls had idiopathic precocious puberty and the only boy had hypothalamic hamartoma. The mean age of presentation was 6. 9 years. All children received GnRHa as monthly injection in an average dose of 190 μgm /kg/month and were regularly followed for evaluation of pubertal suppression, height gain and Bone age advancement.
Highlights
To study if low dose of GnRH analogs (GnRHa) avoided the need for concomitant use of GH therapy while causing adequate pubertal suppression
Conclusion1. Children with CPP could be managed with a lower dose of GnRH analogs (GnRHa) to achieve adequate pubertal suppression (190 μgm/kg/month as opposed to the standard recommended dose of 300 - 750 μgm/kg/month). Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color figure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution
Summary
From 8th APPES Biennial Scientific Meeting Darwin, Australia. 29 October – 1 November 2014. To study if low dose of GnRHa avoided the need for concomitant use of GH therapy while causing adequate pubertal suppression
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
